
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd. demonstrates a positive outlook, supported by a 4% quarter-over-quarter revenue increase in 4Q25, amounting to $174.4 million, alongside an 8% year-over-year growth to $655.4 million for full-year 2025. The company is experiencing notable momentum in the U.S. market, driven by strong domestic sales of Optune Gio and an anticipated boost from newly established national reimbursement in Spain, contributing to growth prospects for 2026. Additionally, ongoing clinical trials, including TRIDENT and KEYNOTE D58, are expected to further enhance growth opportunities by improving access to its therapies across community centers.
Bears say
NovoCure Ltd is facing a negative outlook due to disappointing revenue estimates, reflecting a reduction from $738.9 million to $711.3 million for total revenue in 2026, primarily driven by challenges in the commercial launch of its NSCLC product. Additionally, multiple risks threaten the achievement of financial targets, including potential safety concerns from clinical programs, lower-than-expected efficacy of treatments, increased competition, regulatory uncertainties, and issues related to intellectual property protection. The lack of significant growth in Optune revenues further exacerbates concerns about the company's financial stability and market position.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares